Saturday 17 October 2026
Export EBS’s income statement to Excel — free account
Emergent Biosolutions Inc.
EBS Healthcare Drug Manufacturers Specialty & Generic
Emergent Biosolutions Inc.’s revenue for fiscal 2025 (year ended December 2025) was $742.9 million, down 28.8% from fiscal 2024. In the quarter to June 2026, revenue grew 66.3%, EPS fell 1,486.4%, free cash flow fell 47.7% and total debt fell 12.9%, each against the same quarter a year earlier.
6.38
0.80
−11.14%
Follow EBS
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
28.90 | 24.60 | 47.42 | 50.90 | 15.50 | 10.04 | 0.00 | 0.00 | 0.00 | 13.01 |
Piotroski F-Score |
4 | 7 | 2 | 7 | 7 | 6 | 3 | 3 | 6 | 6 |
P/S ratio |
2.73 | 3.57 | 3.80 | 2.51 | 3.04 | 1.31 | 0.54 | 0.13 | 0.49 | 0.89 |
Altman Z-Score |
3.85 | 9.16 | 2.40 | 2.48 | 3.70 | 2.84 | 0.70 | (0.67) | 0.99 | 1.63 |
P/FCF ratio |
0.00 | 13.08 | 0.00 | 27.48 | 11.95 | 24.20 | 0.00 | 0.00 | 11.59 | 3.39 |
Altman Z″-Score (non-manufacturers) |
5.99 | 10.24 | 2.92 | 3.17 | 4.74 | 5.09 | 1.18 | (2.03) | 1.59 | 3.44 |
Beneish M-Score |
(2.45) | (2.35) | (1.96) | (2.71) | (2.93) | (2.46) | (2.98) | (3.70) | (3.46) | (3.56) |
P/Operating CF |
(105.59) | 25.88 | (17.91) | 22.76 | 19.27 | 7.09 | 6.49 | 4.13 | (6.34) | 8.51 |
P/B ratio |
2.24 | 2.20 | 2.94 | 2.55 | 3.26 | 1.44 | 0.43 | 0.20 | 1.05 | 1.27 |
Price to Tangible BV |
2.56 | 2.70 | 0.00 | 25.49 | 9.13 | 2.95 | 1.37 | 1.60 | 0.00 | 7.68 |
EV/Sales |
2.69 | 3.28 | 4.67 | 3.09 | 3.20 | 1.46 | 1.22 | 0.84 | 1.02 | 1.38 |
EV/EBITDA |
9.15 | 10.92 | 23.89 | 15.02 | 9.03 | 5.07 | 0.00 | 0.00 | 142.08 | 4.98 |
EV/Operating CF |
24.08 | 8.85 | 87.37 | 18.20 | 9.29 | 8.09 | (40.04) | (4.27) | 18.15 | 6.01 |
EV/FCF |
(60.88) | 12.01 | (131.85) | 33.85 | 12.61 | 26.95 | (9.11) | (3.42) | 24.38 | 5.26 |
Quick Ratio |
3.97 | 3.25 | 1.91 | 2.03 | 2.22 | 2.28 | 0.65 | 0.46 | 1.60 | 2.22 |
Current Ratio |
4.82 | 4.85 | 3.10 | 3.17 | 3.11 | 3.40 | 0.98 | 1.04 | 3.69 | 5.01 |
Net Debt/EBITDA |
(0.02) | (0.98) | 4.46 | 2.82 | 0.47 | 0.52 | (48.00) | (2.07) | 74.41 | 1.76 |
Debt/Assets |
27.64% | 1.26% | 35.64% | 34.86% | 30.52% | 28.42% | 44.40% | 47.18% | 47.76% | 43.39% |
Debt/Equity |
0.45 | 0.01 | 0.79 | 0.75 | 0.61 | 0.52 | 1.01 | 1.32 | 1.37 | 1.09 |
Asset Turnover |
0.49 | 0.55 | 0.47 | 0.49 | 0.60 | 0.61 | 0.36 | 0.42 | 0.65 | 0.55 |
Operating CF/Net income |
1.05 | 2.52 | 0.67 | 3.45 | 1.76 | 1.46 | 0.16 | 0.27 | (0.31) | 3.24 |
Capex/Depreciation |
(1.99) | (1.24) | (1.10) | (0.76) | (1.19) | (1.32) | (0.89) | (0.14) | (0.13) | 0.23 |
Interest Coverage |
13.88 | 18.83 | 9.07 | 2.97 | 13.86 | 9.90 | (4.56) | (8.26) | (1.53) | 1.69 |
| 8.25% | 10.95% | 6.52% | 5.19% | 24.07% | 14.32% | (14.08%) | (74.67%) | (33.67%) | 10.46% | |
| 5.16% | 8.10% | 3.80% | 2.39% | 11.71% | 7.51% | (6.91%) | (30.48%) | (11.86%) | 3.88% | |
ROIC |
11.12% | 10.41% | 3.31% | 4.12% | 15.90% | 11.33% | (4.94%) | (32.48%) | (6.53%) | 7.06% |
Return on Tangible Assets |
6.63% | 10.42% | 6.74% | 5.38% | 20.96% | 12.92% | (26.48%) | (185.04%) | (26.96%) | 7.15% |
Average Days of Receivables |
110.87 | 95.07 | 126.47 | 89.34 | 54.18 | 56.53 | 52.00 | 66.44 | 54.04 | 41.37 |
Research and Development Expense of Revenue |
21.87% | 17.36% | 18.25% | 20.45% | 15.08% | 13.26% | 16.85% | 10.62% | 6.77% | 7.16% |
Selling, General and Administrative Expense of Revenue |
29.28% | 25.48% | 25.88% | 24.73% | 19.50% | 19.66% | 30.38% | 35.11% | 29.51% | 25.05% |
Intangible Assets out of Total Assets |
0.08 | 0.16 | 0.46 | 0.42 | 0.32 | 0.28 | 0.30 | 0.31 | 0.36 | 0.33 |
Share Based Compensation of Revenue |
3.78% | 2.71% | 2.97% | 2.41% | 3.28% | 2.39% | 4.04% | 2.20% | 1.72% | 2.18% |
Graham Net Nets |
0.10 | 0.16 | (0.20) | (0.20) | (0.05) | (0.03) | (0.94) | (3.73) | (0.61) | (0.20) |
Graham Number |
19.59 | 30.94 | 23.82 | 22.45 | 59.76 | 54.30 | 0.00 | 0.00 | 0.00 | 14.45 |
Earnings Yield |
3.46% | 4.07% | 2.11% | 1.96% | 6.45% | 9.96% | (33.25%) | (572.59%) | (37.97%) | 7.69% |
Free Cash Flow Yield |
(1.62%) | 7.65% | (0.93%) | 3.64% | 8.37% | 4.13% | (24.89%) | (194.48%) | 8.62% | 29.49% |
Revenue per Share |
12.16 | 13.42 | 15.62 | 21.48 | 29.51 | 33.15 | 22.31 | 20.49 | 19.69 | 13.89 |
Operating CF per Share |
1.36 | 4.98 | 0.83 | 3.65 | 10.17 | 5.99 | (0.68) | (4.03) | 1.11 | 3.19 |
Capex per Share |
(1.90) | (1.31) | (1.39) | (1.69) | (2.68) | (4.19) | (2.75) | (1.01) | (0.28) | 0.46 |
Free Cash Flow per Share |
(0.54) | 3.67 | (0.55) | 1.96 | 7.50 | 1.80 | (3.43) | (5.04) | 0.82 | 3.64 |
Cash per Share |
6.75 | 4.29 | 2.24 | 3.26 | 11.79 | 10.77 | 12.83 | 2.18 | 1.99 | 3.91 |
Shareholders Equity per Share |
14.83 | 21.83 | 20.18 | 21.14 | 27.46 | 30.26 | 27.70 | 12.68 | 9.11 | 9.77 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
14.83 | 21.83 | 20.18 | 21.14 | 27.46 | 30.26 | 27.70 | 12.68 | 9.11 | 9.77 |
Free Cash Flow |
(21.60) | 153.30 | (27.70) | 101.10 | 395.00 | 96.10 | (171.70) | (257.90) | 43.70 | 195.00 |
Working Capital |
404.36 | 385.30 | 420.40 | 469.90 | 811.40 | 898.30 | (18.50) | 28.20 | 436.30 | 530.30 |
Capital Expenditures |
(76.20) | (54.80) | (69.50) | (86.90) | (141.00) | (224.10) | (137.60) | (51.60) | (15.00) | 24.40 |
Net Current Asset Value |
136.31 | 327.50 | (597.70) | (552.60) | (240.30) | (67.90) | (568.20) | (494.40) | (308.20) | (133.50) |
EV/EBIT |
12.46 | 14.82 | 40.67 | 29.99 | 11.48 | 7.59 | 0.00 | 0.00 | 0.00 | 10.24 |
Capex to Sales |
0.16 | 0.10 | 0.09 | 0.08 | 0.09 | 0.13 | 0.12 | 0.05 | 0.01 | (0.03) |
Price to Operating Income |
12.66 | 16.13 | 33.07 | 24.35 | 10.89 | 6.81 | 0.00 | 0.00 | 0.00 | 6.61 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.10 | 0.11 | 0.12 | 0.21 | 0.18 | 0.21 | 0.19 | 0.95 | 0.43 | 0.51 |
Cash ROIC |
(1.90%) | 13.87% | (1.44%) | 4.89% | 13.40% | 3.17% | (5.00%) | (15.91%) | 3.49% | 14.96% |
Accounts Receivable Turnover |
3.63 | 3.81 | 3.75 | 4.08 | 6.20 | 7.02 | 5.15 | 5.99 | 6.04 | 6.22 |
Accounts Payable Turnover |
3.48 | 4.91 | 5.26 | 4.94 | 4.54 | 5.65 | 5.96 | 6.54 | 7.87 | 5.60 |
Inventory Turnover |
1.87 | 1.73 | 1.85 | 2.02 | 1.98 | 2.27 | 1.98 | 2.08 | 2.13 | 1.00 |
Average Days of Payables |
100.13 | 81.28 | 91.39 | 79.82 | 94.80 | 62.89 | 54.51 | 58.06 | 32.63 | 62.21 |
Days of Inventory on Hand |
213.86 | 277.69 | 233.07 | 187.34 | 213.85 | 171.16 | 184.69 | 170.19 | 166.99 | 384.25 |
Average Receivables |
134.48 | 147.29 | 208.60 | 270.90 | 250.80 | 252.80 | 216.95 | 175.10 | 172.75 | 119.35 |
Average Payables |
36.31 | 38.22 | 61.25 | 87.75 | 115.45 | 132.50 | 116.20 | 107.85 | 86.55 | 58.25 |
Average Inventory |
67.44 | 108.40 | 174.30 | 214.15 | 264.75 | 328.90 | 350.75 | 339.80 | 320.30 | 327.55 |
Average Assets |
1,003.80 | 1,020.16 | 1,649.80 | 2,278.35 | 2,605.25 | 2,921.10 | 3,062.65 | 2,494.75 | 1,606.45 | 1,354.15 |
Average Common Equity |
628.11 | 754.25 | 961.60 | 1,049.70 | 1,267.75 | 1,533.00 | 1,503.35 | 1,018.50 | 566.05 | 502.70 |
Columns are period end dates